Study 1 of 23Retatrutide (LY3437943) literatureThe lancet. Diabetes & endocrinologyTop journal2026
Beyond weight loss: multisystem benefits of obesity medications.
Not reported in abstract.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpus9
Preclinical · this one
7
Observational
0
Open-label
1
Randomised
6
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Retatrutide (LY3437943) corpus
BSustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.JCEM case reports · 2026 · n=1 · Total weight loss of 58.8% (-108.7 kg) at 18 months.HumanCCagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.Nature metabolism · 2026 · Not reported in abstract.AnimalDObstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.Clinical oral investigations · 2024 · Not reported in abstract.reviewCCagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.Nature metabolism · 2026 · Not reported in abstract.AnimalBDetection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.Rapid communications in mass spectrometry : RCM · 2023 · n=4 · Limits of detection (LOD) were 6.14 ng/mL in plasma and 2.44 ng/mL in urine.HumanBDetection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.Rapid communications in mass spectrometry : RCM · 2023 · n=4 · Limits of detection in plasma were 6.14 ng/mL and in urine were 2.44 ng/mL.Human